A random forest model to predict the efficacy of anti-PD-1/PD-L1 monoclonal antibody in lung adenocarcinoma

被引：0
|
作者：
Xie, Tongji
Li, Yan
Yang, Lin
Wu, Lige
Yuan, Hanqi
Ying, Jianming
Li Junling
Xing, Puyuan
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Pathol, State Key Lab Mol Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20558
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The safety and efficacy of anti-PD-1/PD-L1 monoclonal antibodies for lung cancer brain metastasis: a systematic review and meta-analysis on brain metastasis
    Delbari, Pouria
    Ahmadvand, Muhammad Hussain
    Mirjani, Mohammad Sina
    Hajikarimloo, Bardia
    Rad, Romina Hamidi
    Kargar-Soleimanabad, Saeed
    Edalat, Mehrshad
    Bahri, Amirmohammad
    Eftekhar, Mohammad Shahir
    Mohammadzadeh, Ibrahim
    Habibi, Mohammad Amin
    NEUROSURGICAL REVIEW, 2025, 48 (01)
  • [42] Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
    Wenxin Zhang
    Xiaohui Pan
    Yanjun Xu
    Hongjie Guo
    Mingming Zheng
    Xi Chen
    Honghai Wu
    Fengming Luan
    Qiaojun He
    Ling Ding
    Bo Yang
    Acta Pharmaceutica Sinica B, 2023, (06) : 2585 - 2600
  • [43] Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
    Qi, Yihang
    Zhang, Lin
    Wang, Zhongzhao
    Kong, Xiangyi
    Zhai, Jie
    Fang, Yi
    Wang, Jing
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [44] Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
    Ken Masuda
    Hidehito Horinouchi
    Midori Tanaka
    Ryoko Higashiyama
    Yuki Shinno
    Jun Sato
    Yuji Matsumoto
    Yusuke Okuma
    Tatsuya Yoshida
    Yasushi Goto
    Noboru Yamamoto
    Yuichiro Ohe
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 245 - 251
  • [45] Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
    Zhang, Wenxin
    Pan, Xiaohui
    Xu, Yanjun
    Guo, Hongjie
    Zheng, Mingming
    Chen, Xi
    Wu, Honghai
    Luan, Fengming
    He, Qiaojun
    Ding, Ling
    Yang, Bo
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (06) : 2585 - 2600
  • [46] NT219 induces tumor PD-L1 expression and potentiates anti-PD-1 efficacy
    de Azevedo, Ricardo Alexandre
    Reuveni, Hadas
    Bar-Eli, Menashe
    Curran, Michael
    CANCER RESEARCH, 2023, 83 (07)
  • [47] DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
    Choi, Seong Hee
    Mani, Muralidharan
    Kim, Jeonghwan
    Cho, Wha Ja
    Martin, Thomas F. J.
    Kim, Jee Hyun
    Chu, Hun Su
    Jeong, Won Jin
    Won, Young-Wook
    Lee, Byung Ju
    Ahn, Byungyong
    Kim, Junil
    Jeon, Do Yong
    Park, Jeong Woo
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [48] Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
    Wang, Luyao
    Yang, Zongxing
    Guo, Fucheng
    Chen, Yurong
    Wei, Jiarui
    Dai, Xiangpeng
    Zhang, Xiaoling
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [49] Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
    Tan, Shuguang
    Zhang, Catherine W-H
    Gao, George F.
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2016, 1
  • [50] Optimizing PD-1 to PD-L1 proximity assays to predict response in patients with advanced melanoma receiving anti-PD-1
    Green, B.
    Will, E.
    Engle, L.
    Deutsch, J. S.
    Lipson, E.
    Szalay, A.
    Sunshine, J. C.
    Taube, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S32 - S32
12345